1. Home
  2. Analysis

Insomnia and drugs of ingredients of abrocitinib (a real world drug study)


Summary:

Insomnia is found among people who take drugs with ingredients of abrocitinib, especially for people who are female, 60+ old , have been taking the drugs for < 1 month. This phase IV clinical study is created by eHealthMe based on reports of 2,111 people who have side effects when taking drugs with ingredients of abrocitinib from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Cibinqo.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 23, 2026

2,111 people reported to have side effects when taking drugs with ingredients of abrocitinib.
Among them, 25 people (1.18%) have Insomnia

What is Insomnia?

Insomnia (sleeplessness) is found to be associated with 3,115 drugs and 5,173 conditions by eHealthMe. Check the latest studies of Insomnia.

Number of reports submitted per year:

Could drugs with ingredients of abrocitinib cause Insomnia?

Time on drugs with ingredients of abrocitinib when people have Insomnia *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Insomnia when taking drugs with ingredients of abrocitinib *:

  • female: 78.26 %
  • male: 21.74 %

Age of people who have Insomnia when taking drugs with ingredients of abrocitinib *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 22.22 %
  • 30-39: 0.0 %
  • 40-49: 5.5600000000000005 %
  • 50-59: 5.5600000000000005 %
  • 60+: 66.67 %

Conditions people have *:

You may use this to check any potential undetected conditions.

  1. Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 11 people, 44.00%
  2. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 4 people, 16.00%

Other drugs people take *:

You may use this to check any potential interacting drugs.

  1. Dupixent: 6 people, 24.00%
  2. Rinvoq: 3 people, 12.00%
  3. Prednisone: 2 people, 8.00%
  4. Methotrexate: 2 people, 8.00%
  5. Hydroxyzine: 2 people, 8.00%
  6. Opzelura: 1 person, 4.00%
  7. Humira: 1 person, 4.00%
  8. Gabapentin: 1 person, 4.00%
  9. Cetirizine Hydrochloride: 1 person, 4.00%

Other side effects people have besides Insomnia *:

You may use this to check any potential undetected side effects.

  1. Dizziness: 8 people, 32.00%
  2. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 8 people, 32.00%
  3. Rashes (redness): 7 people, 28.00%
  4. Itching: 7 people, 28.00%
  5. Drug Ineffective: 5 people, 20.00%
  6. Pneumonia: 5 people, 20.00%
  7. Hormone Level Abnormal: 4 people, 16.00%
  8. Stress And Anxiety: 4 people, 16.00%
  9. Headache (pain in head): 4 people, 16.00%
  10. Urination - Excessive At Night: 3 people, 12.00%

* Approximation only. Some reports may have incomplete information.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Drugs with ingredients of abrocitinib, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on abrocitinib. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.